Dr. Conley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2989 Friends Road
Annapolis, MD 21401Phone+1 410-703-1155
Summary
- Dr. Robert Conley is a psychiatrist in Annapolis, MD; he is Chief Science Officer at Beckley Psytech and is affiliated with University of Maryland Medical Center. He received his medical degree from University of Maryland School of Medicine and has been in practice 40 years. He specializes in neuropsychiatry, pain medicine, and psychopharmacology.
Education & Training
- UPMC Medical EducationResidency, Psychiatry, 1981 - 1985
- The Johns Hopkins UniversityBA, Natural Science, Honors, AED, 1977 - 1981
- University of Maryland School of MedicineClass of 1981, MD, Honors, AOA
Certifications & Licensure
- MD State Medical License 1989 - 2024
- PA State Medical License 1983 - 2008
- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Fellow, American College of Neuropsychopharmacology ACNP
Publications & Presentations
PubMed
- 10 citationsChallenges and complexities in designing cluster headache prevention clinical trials: A narrative review.David W Dodick, Peter J Goadsby, Messoud Ashina, Cristina Tassorelli, Hans-Peter Hundemer
Headache. 2022-04-01 - 77 citationsPhase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.David W. Dodick, Peter J. Goadsby, Christian Lucas, Rigmor Jensen, Jennifer N. Bardos
Cephalalgia. 2020-02-12 - 136 citationsTrial of Galcanezumab in Prevention of Episodic Cluster Headache.Peter J. Goadsby, David W. Dodick, Massimo Leone, Jennifer N. Bardos, Tina M. Oakes
The New England Journal of Medicine. 2019-07-10
Press Mentions
- Mental Health: Superiority of New Schizophrenia Drug Gets ChallengedFebruary 18th, 2020
Grant Support
- The Effects Of The Cannabinoid-1 Receptor Antagonist Rimonabant On Weight...National Institute Of Mental Health2006
- 3 Arm StudyNational Center For Research Resources2004
- New Antipsychotic Strategies In SchizophreniaNational Institute Of Mental Health1997–2001
- New Atypical Neuroleptic Strategies In SchizophreniaNational Institute Of Mental Health1993–1996
Industry Relationships
- Distinguished Scholar, Eli LillyFull time employee2008 - 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: